Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Alto Neuroscience Q3 2026 Results: Net Loss of $25.1M, Loss Widens

Alto Neuroscience reported a net loss of $79.0 million for the nine months ended September 30, 2026, compared to $47.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a private placement and direct shelf offering, ending the period with $319.3 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-25.1-14.2
EPS (diluted, $ a share)$-0.54$-0.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: ANRO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Alto Neuroscience, Inc.: key numbers

Share price
$24.91Close, Nov 17
Market cap
$999M
Shares outstanding
40.11MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Alto Neuroscience, Inc.

All →
4:13 PM ET 8-K
Financial Results

Alto Neuroscience Financial Results

Alto Neuroscience reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $319.8 million following a $100 million financing. The company confirmed its clinical pipeline remains on track, with topline data for its PACE-1 trial in treatment-resistant depression expected in the second half of 2027.

“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027. PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.”

Amit Etkin, M.D., Ph.D., founder and chief executive officer
9:34 PM ET Form 4
Insider Selling

Alto Neuroscience President and CFO Nicholas Conrad Smith Sells $3.57M of Stock

Nicholas Conrad Smith, President and CFO, sold 134,886 shares of Alto Neuroscience, Inc. at $25.78 to $26.87 a share (average $26.45) in 3 transactions, worth $3.57M in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 24,060 (-3.6%).

Value
$3.57M
Shares
134,886
Average price
$26.45
Role
President and CFO
Holding change
-3.6%
Trade date
Sep 29, 2026 to Sep 30, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.